| 영문 | antibiotics | 한글 | 항생제 |
|---|---|---|---|
| 설명 | 미생물이 만들어내는 항생 물질로 된 약제. 다른 미생물이나 생물 세포를 선택적으로 억제하거나 죽인다. 미생물에 의해 생산되며 미생물의 발육 또는 악성종양의 증식을 저지하는 물질이다. 숙주에 무해한 항생물질은 사람-동물-식물의 세균감염증의 치료에 화학요법제로 사용한다. 그 작용메커니즘은 미생물의 세포벽을 합성하는 것을 저해하는 것, 핵산(DNA, RNA) 합성저해, 단백질 합성저해, 보효소합성저해 등이 있다. 작용메커니즘과 화학구조에 따라 β-락탐계(페니실린류), 아미노당류계, 테트라사이클린계, 클로람페니콜계, 폴리펩티드계, 기타(린코마이신, 반코마이신 등)로 분류된다. 항종양항생물질에는 아드리아마이신, 악티노마이신D, 마이토마이신C, 블레오마이신 등이 있다. |
||
| FKBP | FK 506 [macrolide] binding protein |
|---|---|
| TEF | Tracheo-Esophageal Fistula ? Tx 1. Infant Warmer ... |
| NOABX | no antibiotics |
| ORALABX | oral antibiotics |
| AGs | Aminoglycoside antibiotics |
|---|---|
| AB | Antibiotics |
| MLS | Macrolide-lincosamide-streptogramin B |
| MLS | macrolide-lincosamide-streptogramin |
| MLS(B) | macrolide-lincosamide-streptogramin B |
PDGF (혈소판 유래 성장 인자
| antibiotics, macrolide | A group of antibiotics containing a macrocyclic lactone ring linked glycosidically to one or more sugar moieties. These antibiotics are produced by certain species of streptomyces. They often inhibit protein synthesis by binding to the 50s subunits of 70s ribosomes. (12 Dec 1998) |
|---|
| macrolide | <pharmacology> A group of antibiotics produced by various strains of Streptomyces that have a complex macrocyclic structure. They inhibit protein synthesis by blocking the 50S ribosomal subunit. Include erythromycin, carbomycin. Used clinically as broad spectrum antibiotics, particularly against gram-positive bacteria. (18 Nov 1997) |
|---|---|
| macrolide 2'-kinase | <enzyme> Inducible intracellular enzyme which inactivates 14-member ring macrolides at the 2'-oh of the d-desosamine moiety; from an erythromycin-resistant strain of E coli; GTP, itp and ATP can also act as donors; mph(2')i is encoded by mpha and mrx, which have been sequenced Registry number: EC 2.7.1.136 Synonym: oleandomycin 2'-phosphotransferase, macrolide 2'-phosphotransferase, macrolide 2'-phosphotransferase I, mph(2')i (26 Jun 1999) |
| macrolide glycosyltransferase | <enzyme> From streptomyces lividans; utilises udp-glucose as cofactor; substrates include macrolides with 12-, 14-, 15-, or 16-atom cyclic polyketide lactones; enzyme specific for the 2'-oh group of saccharide moieties attached to c-5 of the 16-atom lactone ring Registry number: EC 2.4.1.- Synonym: macrolide glucosyltransferase (26 Jun 1999) |
| antibiotics | Drugs that fight infections. (12 Dec 1998) |
| antibiotics, aminoglycoside | Antibiotics whose structure contains amino sugars attached to an aminocyclitol ring (hexose nucleus) by glycosidic bonds. Aminoglycoside antibiotics are derived from various species of streptomyces and micromonospora or are produced synthetically. They act by inhibiting protein synthesis. (12 Dec 1998) |
| antibiotics, anthracycline | Antibiotics which have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to a sugar molecule. These antibiotics have potent antineoplastic activity. The two best known members of this group are daunorubicin and doxorubicin. Since these agents intercalate with DNA, many DNA functions are adversely affected. Futhermore they interact with cell membranes thereby altering their functions and also generate hydrogen peroxide and hydroxy radicals which are highly destructive to cells. (12 Dec 1998) |
| antibiotics, antifungal | Antibiotics inhibiting the growth of or killing fungi and used in the treatment of various fungal diseases. (12 Dec 1998) |
| antibiotics, antineoplastic | Chemical substances, produced by microorganisms, inhibiting or preventing the development of neoplasms. (12 Dec 1998) |
| antibiotics, antitubercular | Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. (12 Dec 1998) |
| antibiotics, combined | Combination of antibiotics used against difficult-to-treat infections. Antibiotic combinations have been used mainly to broaden the antibacterial spectrum and prevent development of resistance. In some instances these combinations have shown lower toxicity, but drug antagonism may be one of the problems encountered by their use. They may be given simultaneously or sequentially. The drugs need not be in the same dosage form. (12 Dec 1998) |
| antibiotics, glycopeptide | Antibiotics whose structure contains one or more cyclic peptides to which are attached one or more deoxy sugars in glycosidic linkage. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| antibiotics, lactam | Compounds containing a four-membered ring with an amide nitrogen and a keto group. This configuration includes bacteriostatic, cell-wall inhibiting antibiotics, such as penicillins and cephalosporins; their analogs and derivatives, such as the penem (or penam) compounds; clavulanic acids; and monobactams. They are substrates for and may act as inhibitors of bacterial beta-lactamases. (12 Dec 1998) |
| antibiotics, peptide | Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| antibiotics, tetracycline | <chemical> Broad-spectrum natural and semisynthetic antibiotics with a naphthacene structure obtained from various streptomyces species. Pharmacological action: protein synthesis inhibitor. (12 Dec 1998) |
| intravenous antibiotics | The administration of an antibiotic solution into the venous circulation. (27 Sep 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|